KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Debt Repayments (2021 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $1.1 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Debt Repayments changed N/A year-over-year to $1.1 billion, compared with a TTM value of -$414.2 million through Sep 2025, changed N/A, and an annual FY2025 reading of $1.2 billion, changed N/A over the prior year.
  • Long-Term Debt Repayments was $1.1 billion for Q3 2025 at Alnylam Pharmaceuticals, up from -$1.5 billion in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.1 billion in Q3 2025 and bottomed at -$1.5 billion in Q4 2022.
  • Average Long-Term Debt Repayments over 3 years is $28.6 million, with a median of $500.0 million recorded in 2021.
  • Peak annual rise in Long-Term Debt Repayments hit 404.84% in 2022, while the deepest fall reached 404.84% in 2022.
  • Year by year, Long-Term Debt Repayments stood at $500.0 million in 2021, then tumbled by 404.84% to -$1.5 billion in 2022, then surged by 172.82% to $1.1 billion in 2025.
  • Business Quant data shows Long-Term Debt Repayments for ALNY at $1.1 billion in Q3 2025, -$1.5 billion in Q4 2022, and $500.0 million in Q4 2021.